Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of RO6958688 in CEA-positive advanced solid tumors
NL-OMON46944Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2015
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of cibisatamab in Nonhematologic neoplasms, gastrointestinal cancer, colorectal cancer (CRC) and 2 more (2 arms), sponsored by Roche. Primary endpoints: Safety profile, Maximum tolerated dose and recommended dose/schedule and 3 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
cibisatamab
03
Conditions
Nonhematologic neoplasmsgastrointestinal cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NL-OMON46944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46944.